Sulfacetamide
Sulfisoxazole
Sulfadiazine
Drug Residues
Sulfamethoxazole
Dihydropteroate Synthase
4-Aminobenzoic Acid
Trimethoprim
R Factors
Dapsone
Formiminoglutamic Acid
Carbonic Anhydrase Inhibitors
Aminobenzoates
Drug Hypersensitivity
Chemistry Techniques, Synthetic
Drug Resistance, Microbial
Veterinary Drugs
Anti-Infective Agents
Potassium Iodide
Sulfanilamides
Molecular Structure
Trimethoprim-Sulfamethoxazole Combination
Microbial Sensitivity Tests
Extrachromosomal Inheritance
Carbonic Anhydrases
Conjugation, Genetic
Drug Eruptions
Salmonella enterica
Drug Resistance, Multiple, Bacterial
Streptomycin
Transferases
Structure-Activity Relationship
Solid Phase Extraction
Escherichia coli
Folic Acid Antagonists
Stereoisomerism
Integrons
Plasmids
Bacteriophage Typing
Salmonella typhimurium
Amides
Drug Resistance, Bacterial
Electrophoresis, Gel, Pulsed-Field
Drug Resistance, Multiple
Enterobacteriaceae
Chromatography, High Pressure Liquid
Serotyping
Enzyme Inhibitors
Culture Media
Swine
Molecular Sequence Data
Regulation of cardiac L-type Ca2+ channel by coexpression of G(alpha s) in Xenopus oocytes. (1/6807)
Activation of G(alpha s) via beta-adrenergic receptors enhances the activity of cardiac voltage-dependent Ca2+ channels of the L-type, mainly via protein kinase A (PKA)-dependent phosphorylation. Contribution of a PKA-independent effect of G(alpha s) has been proposed but remains controversial. We demonstrate that, in Xenopus oocytes, antisense knockdown of endogenous G(alpha s) reduced, whereas coexpression of G(alpha s) enhanced, currents via expressed cardiac L-type channels, independently of the presence of the auxiliary subunits alpha2/delta or beta2A. Coexpression of G(alpha s) did not increase the amount of alpha1C protein in whole oocytes or in the plasma membrane (measured immunochemically). Activation of coexpressed beta2 adrenergic receptors did not cause a detectable enhancement of channel activity; rather, a small cAMP-dependent decrease was observed. We conclude that coexpression of G(alpha s), but not its acute activation via beta-adrenergic receptors, enhances the activity of the cardiac L-type Ca2+ channel via a PKA-independent effect on the alpha1C subunit. (+info)[3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum. (2/6807)
1. The primary aim of this investigation was to determine whether binding sites corresponding to the 5-HT7 receptor could be detected in smooth muscle of the rat jejunum. Binding studies in rat brain (whole brain minus cerebellum) and guinea-pig ileal longitudinal muscle were also undertaken in order to compare the binding characteristics of these tissues. Studies were performed using [3H]-mesulergine, as it has a high affinity for 5-HT7 receptors. 2. In the rat brain and guinea-pig ileum, pKD values for [3H]-mesulergine of 8.0 +/- 0.04 and 7.9 +/- 0.11 (n = 3) and Bmax values of 9.9 +/- 0.3 and 21.5 +/- 4.9 fmol mg(-1) protein were obtained respectively, but no binding was detected in the rat jejunum. [3H]-mesulergine binding in the rat brain and guinea-pig ileum was displaced with the agonists 5-carboxamidotryptamine (5-CT) > 5-hydroxytryptamine (5-HT) > or = 5-methoxytryptamine (5-MeOT) > sumatriptan and the antagonists risperidone > or = LSD > or = metergoline > ritanserin > > pindolol. 3. Despite the lack of [3H]-mesulergine binding in the rat jejunum, functional studies undertaken revealed a biphasic contractile response to 5-HT which was partly blocked by ondansetron (1 microM). The residual response was present in over 50% of tissues studied and was found to be inhibited by risperidone > LSD > metergoline > mesulergine = ritanserin > pindolol, but was unaffected by RS 102221 (3 microM), cinanserin (30 nM), yohimbine (0.1 microM) and GR 113808 (1 microM). In addition, the agonist order of potency was 5-CT > 5-HT > 5-MeOT > sumatriptan. 4. In conclusion, binding studies performed with [3H]-mesulergine were able to detect 5-HT7 sites in rat brain and guinea-pig ileum, but not in rat jejunum, where a functional 5-HT7-like receptor was present. (+info)Effects of tumour necrosis factor-alpha on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. (3/6807)
1. The cardiac depressant actions of TNF were investigated in the isolated perfused rat heart under constant flow (10 ml min(-1)) and constant pressure (70 mmHg) conditions, using a recirculating (50 ml) mode of perfusion. 2. Under constant flow conditions TNF (20 ng ml(-1)) caused an early (< 25 min) decrease in left ventricular developed pressure (LVDP), which was maintained for 90 min (LVDP after 90 min: control vs TNF; 110 +/- 4 vs 82 +/- 10 mmHg, P < 0.01). 3. The depression in cardiac function seen with TNF under constant flow conditions, was blocked by the ceramidase inhibitor N-oleoylethanolamine (NOE), 1 microM, (LVDP after 90 min: TNF vs TNF with NOE; 82 +/- 10 vs 11 +/- 5 mmHg, P < 0.05). 4. In hearts perfused at constant pressure, TNF caused a decrease in coronary flow rate (change in flow 20 min after TNF: control vs TNF; -3.0 +/- 0.9 vs -8.7 +/- 1.2 ml min(-1), P < 0.01). This was paralleled by a negative inotropic effect (change in LVDP 20 min after TNF: control vs TNF; -17 +/- 7 vs -46 +/- 6 mmHg, P < 0.01). The decline in function was more rapid and more severe than that seen under conditions of constant flow. 5. These data indicate that cardiac function can be disrupted by TNF on two levels, firstly via a direct, ceramidase dependant negative inotropic effect, and secondly via an indirect coronary vasoconstriction. (+info)Modulation of chloride, potassium and bicarbonate transport by muscarinic receptors in a human adenocarcinoma cell line. (4/6807)
1. Short-circuit current (I(SC)) responses to carbachol (CCh) were investigated in Colony 1 epithelia, a subpopulation of the HCA-7 adenocarcinoma cell line. In Krebs-Henseleit (KH) buffer, CCh responses consisted of three I(SC) components: an unusual rapid decrease (the 10 s spike) followed by an upward spike at 30 s and a slower transient increase (the 2 min peak). This response was not potentiated by forskolin; rather, CCh inhibited cyclic AMP-stimulated I(SC). 2. In HCO3- free buffer, the decrease in forskolin-elevated I(SC) after CCh was reduced, although the interactions between CCh and forskolin remained at best additive rather than synergistic. When Cl- anions were replaced by gluconate, both Ca2+- and cyclic AMP-mediated electrogenic responses were significantly inhibited. 3. Basolateral Ba2+ (1-10 mM) and 293B (10 microM) selectively inhibited forskolin stimulation of I(SC), without altering the effects of CCh. Under Ba2+- or 293B-treated conditions, CCh responses were potentiated by pretreatment with forskolin. 4. Basolateral charybdotoxin (50 nM) significantly increased the size of the 10 s spike of CCh responses in both KH and HCO3- free medium, without affecting the 2 min peak. The enhanced 10 s spike was inhibited by prior addition of 5 mM apical Ba2+. Charybdotoxin did not affect forskolin responses. 5. In epithelial layers prestimulated with forskolin, the muscarinic antagonists atropine and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP, both at 100 nM) abolished subsequent 10 microM CCh responses. Following addition of p-fluoro hexahydro-sila-difenidol (pF-HHSiD, 10 microM) or pirenzepine (1 microM), qualitative changes in the CCh response time-profile also indicated a rightward shift of the agonist concentration-response curve; however, 1 microM gallamine had no effect. These results suggest that a single M3-like receptor subtype mediates the secretory response to CCh. 6. It is concluded that CCh and forskolin activate discrete populations of basolateral K+ channels gated by either Ca2+ or cyclic AMP, but that the Cl- permeability of the apical membrane may limit their combined effects on electrogenic Cl- secretion. In addition, CCh activates a Ba2+-sensitive apical K+ conductance leading to electrogenic K+ transport. Both agents may also modulate HCO3- secretion through a mechanism at least partially dependent on carbonic anhydrase. (+info)Mechanisms involved in the metabotropic glutamate receptor-enhancement of NMDA-mediated motoneurone responses in frog spinal cord. (5/6807)
1. The metabotropic glutamate receptor (mGluR) agonist trans-(+/-)-1-amino-1,3-cyclopentanedicarboxylic acid (trans-ACPD) (10-100 microM) depolarized isolated frog spinal cord motoneurones, a process sensitive to kynurenate (1.0 mM) and tetrodotoxin (TTX) (0.783 microM). 2. In the presence of NMDA open channel blockers [Mg2+; (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK801); 3,5-dimethyl-1-adamantanamine hydrochloride (memantine)] and TTX, trans-ACPD significantly potentiated NMDA-induced motoneurone depolarizations, but not alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionate (AMPA)- or kainate-induced depolarizations. 3. NMDA potentiation was blocked by (RS)-alpha-methyl-4-carboxyphenylglycine (MCPG) (240 microM), but not by alpha-methyl-(2S,3S,4S)-alpha-(carboxycyclopropyl)-glycine (MCCG) (290 microM) or by alpha-methyl-(S)-2-amino-4-phosphonobutyrate (L-MAP4) (250 microM), and was mimicked by 3,5-dihydroxyphenylglycine (DHPG) (30 microM), but not by L(+)-2-amino-4-phosphonobutyrate (L-AP4) (100 microM). Therefore, trans-ACPD's facilitatory effects appear to involve group I mGluRs. 4. Potentiation was prevented by the G-protein decoupling agent pertussis toxin (3-6 ng ml(-1), 36 h preincubation). The protein kinase C inhibitors staurosporine (2.0 microM) and N-(2-aminoethyl)-5-isoquinolinesulphonamide HCI (H9) (77 microM) did not significantly reduce enhanced NMDA responses. Protein kinase C activation with phorbol-12-myristate 13-acetate (5.0 microM) had no effect. 5. Intracellular Ca2+ depletion with thapsigargin (0.1 microM) (which inhibits Ca2+/ATPase), 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetracetic acid acetyl methyl ester (BAPTA-AM) (50 microM) (which buffers elevations of [Ca2+]i), and bathing spinal cords in nominally Ca2+-free medium all reduced trans-ACPD's effects. 6. The calmodulin antagonists N-(6-aminohexyl)-5-chloro-1-naphthalenesulphonamide (W7) (100 microM) and chlorpromazine (100 microM) diminished the potentiation. 7. In summary, group I mGluRs selectively facilitate NMDA-depolarization of frog motoneurones via a G-protein, a rise in [Ca2+]i from the presumed generation of phosphoinositides, binding of Ca2+ to calmodulin, and lessening of the Mg2+-produced channel block of the NMDA receptor. (+info)Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. (6/6807)
Amprenavir is a human immunodeficiency virus (HIV) protease inhibitor with a favorable pharmacokinetic profile and good in vitro activity. Ninety-two lamivudine- and protease inhibitor-naive individuals with >/=50 CD4 cells/mm3 and >/=5000 HIV RNA copies/mL were assigned amprenavir (1200 mg) alone or with zidovudine (300 mg) plus lamivudine (150 mg), all given every 12 h. After a median follow-up of 88 days, the findings of a planned interim review resulted in termination of the amprenavir monotherapy arm. Among 85 subjects with confirmed plasma HIV RNA determination, 15 of 42 monotherapy versus 1 of 43 triple-therapy subjects had an HIV RNA increase above baseline or 1 log10 above nadir (P=.0001). For subjects taking triple therapy at 24 weeks, the median decrease in HIV RNA was 2.04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy. (+info)Isoforms of the Na-K-2Cl cotransporter in murine TAL II. Functional characterization and activation by cAMP. (7/6807)
The functional properties of alternatively spliced isoforms of the mouse apical Na+-K+-2Cl- cotransporter (mBSC1) were examined, using expression in Xenopus oocytes and measurement of 22Na+ or 86Rb+ uptake. A total of six isoforms, generated by the combinatorial association of three 5' exon cassettes (A, B, and F) with two alternative 3' ends, are expressed in mouse thick ascending limb (TAL) [see companion article, D. B. Mount, A. Baekgaard, A. E. Hall, C. Plata, J. Xu, D. R. Beier, G. Gamba, and S. C. Hebert. Am. J. Physiol. 276 (Renal Physiol. 45): F347-F358, 1999]. The two 3' ends predict COOH-terminal cytoplasmic domains of 129 amino acids (the C4 COOH terminus) and 457 amino acids (the C9 terminus). The three C9 isoforms (mBSC1-A9/F9/B9) all express Na+-K+-2Cl- cotransport activity, whereas C4 isoforms are nonfunctional in Xenopus oocytes. Activation or inhibition of protein kinase A (PKA) does not affect the activity of the C9 isoforms. The coinjection of mBSC1-A4 with mBSC1-F9 reduces tracer uptake, compared with mBSC1-F9 alone, an effect of C4 isoforms that is partially reversed by the addition of cAMP-IBMX to the uptake medium. The inhibitory effect of C4 isoforms is a dose-dependent function of the alternatively spliced COOH terminus. Isoforms with a C4 COOH terminus thus exert a dominant negative effect on Na+-K+-2Cl- cotransport, a property that is reversed by the activation of PKA. This interaction between coexpressed COOH-terminal isoforms of mBSC1 may account for the regulation of Na+-K+-2Cl- cotransport in the mouse TAL by hormones that generate cAMP. (+info)Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. (8/6807)
OBJECTIVE: 5-HT4 receptors are present in human atrial cells and their stimulation has been implicated in the genesis of atrial arrhythmias including atrial fibrillation. An I(f)-like current has been recorded in human atrial myocytes, where it is modulated by beta-adrenergic stimulation. In the present study, we investigated the effect of serotonin (5-hydroxytryptamine, 5-HT) on I(f) electrophysiological properties, in order to get an insight into the possible contribution of I(f) to the arrhythmogenic action of 5-HT in human atria. METHODS: Human atrial myocytes were isolated by enzymatic digestion from samples of atrial appendage of patients undergoing coeffective cardiac surgery. Patch-clamped cells were superfused with a modified Tyrode's solution in order to amplify I(f) and reduce overlapping currents. RESULTS AND CONCLUSIONS: A time-dependent, cesium-sensitive increasing inward current, that we had previously described having the electrophysiological properties of the pacemaker current I(f), was elicited by negative steps (-60 to -130 mV) from a holding potential of -40 mV. Boltzmann fit of control activation curves gave a midpoint (V1/2) of -88.9 +/- 2.6 mV (n = 14). 5-HT (1 microM) consistently caused a positive shift of V1/2 of 11.0 +/- 2.0 mV (n = 8, p < 0.001) of the activation curve toward less negative potentials, thus increasing the amount of current activated by clamp steps near the physiological maximum diastolic potential of these cells. The effect was dose-dependent, the EC50 being 0.14 microM. Maximum current amplitude was not changed by 5-HT. 5-HT did not increase I(f) amplitude when the current was maximally activated by cAMP perfused into the cell. The selective 5-HT4 antagonists, DAU 6285 (10 microM) and GR 125487 (1 microM), completely prevented the effect of 5-HT on I(f). The shift of V1/2 caused by 1 microM 5-HT in the presence of DAU 6285 or GR 125487 was 0.3 +/- 1 mV (n = 6) and 1.0 +/- 0.6 mV (n = 5), respectively (p < 0.01 versus 5-HT alone). The effect of 5-HT4 receptor blockade was specific, since neither DAU 6285 nor GR 125487 prevented the effect of 1 microM isoprenaline on I(f). Thus, 5-HT4 stimulation increases I(f) in human atrial myocytes; this effect may contribute to the arrhythmogenic action of 5-HT in human atrium. (+info)There are several different types of drug hypersensitivity reactions, including:
1. Maculopapular exanthema (MPE): This is a type of allergic reaction that causes a red, itchy rash to appear on the skin. It can be caused by a variety of medications, including antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs).
2. Exfoliative dermatitis: This is a more severe form of MPE that can cause widespread scaling and peeling of the skin. It is often associated with reactions to antibiotics and other medications.
3. Stevens-Johnson syndrome (SJS): This is a rare but potentially life-threatening condition that can be caused by certain medications, including antibiotics and NSAIDs. SJS can cause blisters to form on the skin and mucous membranes, as well as fever and fatigue.
4. Toxic epidermal necrolysis (TEN): This is a severe and potentially life-threatening condition that can be caused by certain medications, including antibiotics and NSAIDs. TEN can cause widespread peeling of the skin, as well as fever and fatigue.
5. Anaphylaxis: This is a severe allergic reaction that can be caused by a variety of medications, including antibiotics and NSAIDs. It can cause symptoms such as hives, itching, swelling, and difficulty breathing.
Drug hypersensitivity reactions can be diagnosed through a combination of physical examination, medical history, and laboratory tests. Treatment typically involves discontinuing the medication that is causing the reaction, as well as providing supportive care to manage symptoms such as fever, itching, and pain. In severe cases, hospitalization may be necessary to monitor and treat the reaction.
Prevention of drug hypersensitivity reactions can be challenging, but there are several strategies that can help reduce the risk. These include:
1. Gradual dose escalation: When starting a new medication, it is important to gradually increase the dose over time to allow the body to adjust.
2. Monitoring for signs of a reaction: Patients should be monitored closely for signs of a reaction, such as hives, itching, or difficulty breathing.
3. Avoiding certain medications: In some cases, it may be necessary to avoid certain medications that are known to cause hypersensitivity reactions.
4. Skin testing: Skin testing can be used to determine whether a patient is allergic to a particular medication before starting treatment.
5. Desensitization: In some cases, desensitization therapy may be used to gradually expose the patient to the medication that is causing the reaction, with the goal of reducing the risk of an adverse event.
Symptoms of nocardiosis can vary depending on the site of infection and severity of disease. Respiratory symptoms may include cough, fever, chest pain, and shortness of breath. Skin infections may cause swelling, redness, and warmth at the site of infection. Bone and joint infections can lead to pain, swelling, and limited mobility.
Diagnosis is based on a combination of clinical findings, laboratory tests, and radiographic imaging. Laboratory tests may include blood cultures, polymerase chain reaction (PCR), and other techniques to detect the presence of Nocardia in body fluids or tissues. Imaging studies such as chest X-rays, computed tomography (CT) scans, or magnetic resonance imaging (MRI) may be used to evaluate the extent of disease.
Treatment of nocardiosis typically involves a combination of antibiotics and surgical debridement of infected tissues. The choice of antibiotics depends on the severity and location of infection, as well as the patient's age, health status, and other medical conditions. Surgical intervention may be necessary to drain abscesses, repair damaged tissues, or remove infected bone or joint segments.
Preventive measures for nocardiosis include avoiding exposure to risk factors such as soil or contaminated water, practicing good hygiene and infection control practices, and following proper sterilization techniques when handling instruments or equipment. Vaccination against Nocardia is not available, and there is currently no effective prophylactic therapy for nocardiosis.
Nocardiosis can be a challenging disease to diagnose and treat, particularly in cases of disseminated infection or those with underlying medical conditions. Prompt recognition and aggressive management are critical to improving patient outcomes.
Types of Drug Eruptions:
1. Maculopapular exanthema (MPE): This is a common type of drug eruption characterized by flat, red patches on the skin that may be accompanied by small bumps or hives. MPE typically occurs within 1-2 weeks of starting a new medication and resolves once the medication is discontinued.
2. Stevens-Johnson syndrome (SJS): This is a more severe type of drug eruption that can cause blisters, skin sloughing, and mucosal lesions. SJS typically occurs within 2-4 weeks of starting a new medication and can be life-threatening in some cases.
3. Toxic epidermal necrolysis (TEN): This is a severe, life-threatening type of drug eruption that can cause widespread skin death and mucosal lesions. TEN typically occurs within 2-4 weeks of starting a new medication and requires immediate hospitalization and treatment.
Causes of Drug Eruptions:
1. Allergic reactions to medications: This is the most common cause of drug eruptions. The body's immune system overreacts to certain medications, leading to skin symptoms.
2. Adverse effects of medications: Certain medications can cause skin symptoms as a side effect, even if the person is not allergic to them.
3. Infections: Bacterial, fungal, or viral infections can cause drug eruptions, particularly if the medication is used to treat the infection.
4. Autoimmune disorders: Certain autoimmune disorders, such as lupus or rheumatoid arthritis, can increase the risk of developing drug eruptions.
Diagnosis and Treatment of Drug Eruptions:
1. Medical history and physical examination: A thorough medical history and physical examination are essential to diagnose a drug eruption. The healthcare provider will look for patterns of skin symptoms that may be related to a specific medication.
2. Skin biopsy: In some cases, a skin biopsy may be necessary to confirm the diagnosis of a drug eruption and to rule out other conditions.
3. Medication history: The healthcare provider will ask about all medications taken by the patient, including over-the-counter medications and supplements.
4. Treatment: Depending on the severity of the drug eruption, treatment may include stopping the offending medication, administering corticosteroids or other immunosuppressive medications, and providing supportive care to manage symptoms such as itching, pain, and infection. In severe cases, hospitalization may be necessary.
5. Monitoring: Patients with a history of drug eruptions should be closely monitored by their healthcare provider when starting new medications, and any changes in their skin should be reported promptly.
Prevention of Drug Eruptions:
1. Allergy testing: Before starting a new medication, the healthcare provider may perform allergy testing to determine the patient's sensitivity to specific medications.
2. Medication history: The healthcare provider should take a thorough medication history to identify potential allergens and avoid prescribing similar medications that may cause an adverse reaction.
3. Gradual introduction of new medications: When starting a new medication, it is recommended to introduce the medication gradually in small doses to monitor for any signs of an adverse reaction.
4. Monitoring: Patients should be closely monitored when starting new medications, and any changes in their skin or symptoms should be reported promptly to their healthcare provider.
5. Avoiding certain medications: In some cases, it may be necessary to avoid certain medications that are more likely to cause a drug eruption based on the patient's medical history and other factors.
Conclusion:
Drug eruptions can present with various symptoms and can be challenging to diagnose. A thorough medical history and physical examination are essential to diagnose a drug eruption. Treatment depends on the severity of the reaction and may include stopping the offending medication, administering corticosteroids, and providing supportive care. Prevention is key, and healthcare providers should be aware of potential allergens and take steps to minimize the risk of adverse reactions. By being vigilant and proactive, healthcare providers can help prevent drug eruptions and ensure the best possible outcomes for their patients.
Prevention of Salmonella Infections includes proper food handling and storage practices, such as cooking foods to the correct temperature, storing foods at the right refrigerator temperature, and washing hands frequently. Vaccines are also available for people who are at high risk of developing severe Salmonella infections.
Complications of a Salmonella Infection can include dehydration, bacteremia (the presence of bacteria in the bloodstream), and meningitis (inflammation of the lining around the brain and spinal cord). In rare cases, a Salmonella infection can lead to long-term health problems such as irritable bowel syndrome or reactive arthritis.
Overall, prompt treatment and proper prevention measures are important for reducing the risk of complications from a Salmonella infection.
The term "Salmonella Infections, Animal" is used to distinguish these infections from Salmonella infections that are caused by contaminated food or water, which are referred to as "Salmonella Infections, Human."
List of sulfonamides
Sulfonamide
Sulfonamide (disambiguation)
Perfluorobutane sulfonamide
Sulfonamide (medicine)
Sulfonamide hypersensitivity syndrome
Indane-5-sulfonamide
Sulfamethoxazole
Coccidiosis
4-Aminobenzoic acid
Sulfadimethoxine
Dihydropteroate synthase inhibitor
Gerhard Domagk
Folate
Healthcare in Germany
Tosyl group
Hydroxylamine-O-sulfonic acid
Antimicrobial resistance
Broad-spectrum antibiotic
Nazi human experimentation
Glysobuzole
Altitude sickness
Unethical human experimentation
Amine
Sulfadimidine
Sulfaguanidine
Perfluorooctanesulfonamide
Chinchilla
Oxybuprocaine
Nitrofurantoin
Sulfonamide Allergies - PubMed
DailyMed - Search Results for Sulfonamide Antimicrobial
Sulfonamides - PubMed
Fixed Drug Eruption Associated with Sulfonamides Sold in Latino Grocery Stores - Greater Washington, DC, Area, 2012-2013
Browsing Journal Articles by Subject "Sulfonamides"
720 - Sulfonamides in fish | LGC Standards
6043 - Buchwald-Hartwig Reaction - Sulfonamides
An Easy Microwave-Assisted Synthesis of Sulfonamides Directly from Sulfonic Acids
Sulfonamide-01 | C22H23N3O5S | CID 11532283 - PubChem
N-Ethylperfluorooctane sulphonamide - Find commodity data - UK Trade Info
2-Amino-9-(β-D-ribofuranosyl)-9H-purine-6-sulfonamide | C10H14N6O6S | ChemSpider
N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide - Ontology Report - Rat Genome Database
2935 10 00 - N-Methylperfluorooctane sulphonamide - EU Vocabularies - Publications Office of the EU
Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans...
DISSERTATIONS.SE: Analysis of fluoroalkyl sulfonamide (FASA) based copolymers - an indirect source of non-polymeric PFAS
NIH VideoCast - New Drugs, Old Problems: The Sulfonamide Revolution and Children's Health Care Delivery in the United States,...
Inquiry for N-methyl-N-Nitroso-p-Toluene Sulfonamide 80-11-5 of China N-methyl-N-Nitroso-p-Toluene Sulfonamide 80-11-5 Suppliers
US Patent for Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof Patent (Patent # 10,385,036 issued...
A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)<...
Sulfonamides | Antibiotics
What Are Sulfonamides?
Subjects: Sulfonamides - Digital Collections - National Library of Medicine Search Results
sulfonamide
Sulfonamides Test kit for Milk
en
Qualitative or Quantitative Antibiotic Sulfonamides ELISA Test Kit
Sulfonamide derivatives diuretics | Affinity Biosciences
Antibiotics12
- The sulfonamides represent a large class of antibiotics that have multiple clinical uses. (nih.gov)
- The sulfonamides were the first effective antibiotics to be introduced into clinical medicine and have been in use continuously since the 1930's. (nih.gov)
- Unfortunately, bacterial resistance to sulfonamides is now common, and their use has decreased with the introduction of more potent classes of antibiotics. (nih.gov)
- Sulfonamides are a group of antibiotics which are bacteriostatic in nature and selectively toxic to bacterial cells. (pharmastate.academy)
- The discovery of sulfonamides paved the way for the widespread use of antibiotics. (urdujobz.com)
- Cutaneous adverse reactions to sulfonamide antibiotics. (who.int)
- Background: Sulfonamides are divided into two main groups which are sulfonamide antibiotics and sulfonamide non-antibiotics. (who.int)
- The wide use of sulfonamide antibiotics leads to increasing incidence of sulfonamide cutaneous reactions. (who.int)
- Objective: The purpose of this study is to explore the cutaneous manifestations induced by sulfonamide antibiotics in a large number of Thai patients, including human immunodeficiency virus (HIV) and non-HIV infected individuals. (who.int)
- Methods: We retrospectively studied 191 patients with sulfonamide antibiotics cutaneous reactions attending the adverse drug reaction center, Siriraj Hospital, Bangkok between 2006 and 2010. (who.int)
- Details for: Antibiotics, sulfonamides, and public health. (who.int)
- Sulfonamides are used in many drugs including antibiotics and Viagra as well as in agrochemicals and dyes, which makes them an important class of molecules for the pharmaceutical and chemical industries. (eurekalert.org)
Antibiotic5
- The Baczol Antigripal ingredients included the sulfonamide-containing antibiotic trimethoprim-sulfamethoxazole (TMP/SMX), which is a common cause of fixed drug eruption. (cdc.gov)
- Unfortunately, gonococci - the species of bacteria that cause gonorrhea - have been evolving resistance to every antibiotic we've thrown at them, including sulfonamides, penicillins, tetracyclines, macrolides, fluoroquinolones, and narrow-spectrum cephalosporins. (advocatesaz.org)
- Indeed, antibiotic resistance was first documented in the 1940s, just years after sulfonamides and penicillin were introduced as the first effective cures for gonorrhea. (advocatesaz.org)
- Sulfonamides (SAs) are group of synthetic antibiotic agents that have been widely used for therapeutic and prophylactic purposes in both animals and human. (mzfoodtest.com)
- The AnticFast® Beta-lactams & Tetracyclines & Sulfonamides Rapid Test Kit is a lateral flow assay that determines a qualitative level for the presence of beta-lactams, tetracyclines and sulfonamides antibiotic residues in raw cow's milk. (everestinstruments.in)
Primary sulfonamides1
- A little optimization of the reaction demonstrated that reacting a nucleophile at low temperature with t -BuONSO was enough to obtain primary sulfonamides in high yield. (galchimia.com)
Antimicrobial2
- As one of the earliest developed antimicrobial classes, sulfonamides remain important therapeutic options for the empiric and definitive treatment of various infectious diseases. (nih.gov)
- Sulfonamides have a wide range of antimicrobial activity against both gram-positive and -negative organisms. (nih.gov)
Residues1
- HPLC/GC-MS method is now widely used in the detection of sulfonamides residues, but its high cost and complex operation make it unacceptable. (mzfoodtest.com)
Synthesis3
- An easy and handy synthesis of sulfonamides directly from sulfonic acids or its sodium salts is performed under microwave irradiation, has shown a good functional group tolerance, and is high yielding. (organic-chemistry.org)
- In 2018, they published a method based on the copper-catalyzed synthesis of sulfonamides using DABSO (a SO 2 surrogate), boronic acids, and amines. (galchimia.com)
- Primary Sulfonamide Synthesis Using the Sulfinylamine Reagent N -Sulfinyl- O -( tert butyl) hydroxylamine, t -BuONSO. (galchimia.com)
Tetracyclines1
- The AnticFast® Beta-lactams & Tetracyclines & Sulfonamides Rapid Test Kit has the capacity for 96 determinations. (everestinstruments.in)
Resistance1
- In this paper, Luria and Oakberg reported their findings of studies in which they determined that at least five different mutations affect the sulfonamide resistance of S. aureus. (nih.gov)
Bacterial3
- They are considered bacteriostatic and appear to act by inhibition of bacterial biosynthesis of folic acid, which is needed for cell growth, at least in those bacteria that are sensitive to sulfonamides. (nih.gov)
- Sulfonamides, or "sulfa drugs", are drugs used to treat bacterial infections. (urdujobz.com)
- Sulfonamides are a group of medicines used to treat bacterial infections, urinary tract infections (UTIs), and other conditions. (everydayhealth.com)
Drugs1
- The investigators also searched the medical literature but found no cases of fixed drug eruption attributed to sulfonamide-containing drugs sold without prescription. (cdc.gov)
Widely2
- However, sulfonamides are still widely used especially for urinary tract infections in combination with trimethoprim and for treatment or prevention of parasitic (toxoplasmosis, pneumocystosis jiroveci) and malarial infections usually combined with trimethoprim or pyrimethamine. (nih.gov)
- Sulfonamides with 5-aminosalicyclic acid are the structural components of sulfasalazine, which is widely used for long term management of inflammatory bowel disease. (nih.gov)
Allergy1
- In the general population, approximately 3-8% of patients are reported to experience a sulfonamide allergy. (nih.gov)
Milk1
- Do not drink milk while taking sulfonamide. (urdujobz.com)
Methods1
- The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof. (justia.com)
Group2
- A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. (mcw.edu)
- The sulfonamide group is one of those chemical moieties that have been around for a long, long time. (galchimia.com)
Birth1
- Animal studies have shown that sulfonamides can cause birth defects. (urdujobz.com)
Indirect1
- Sulfonamides ELISA Test Kit is an indirect competitive enzyme-labeled immunoassay. (mzfoodtest.com)
Preparation1
- In short, they have come up with one of those reactions that can be potentially applied to the preparation of sulfonamides in one step (demonstrated with a precursor of Celecoxib), as long as the molecule does not have groups that are incompatible with the formation of the organometallic nucleophile. (galchimia.com)
Chemistry1
- Our technique of electrochemical production of sulfonamides represents a completely new approach in chemistry that can now be applied to a number of other reactions. (eurekalert.org)
High3
- The aryl sulfonamide and tetrahydro-γ- carboline substructures were required for high antischistosomal activity. (bvsalud.org)
- To their surprise, the reaction of t -BuONSO with an arylmagnesium bromide in the presence of morpholine did not yield the expected secondary sulfonamide, but the primary sulfonamide in high yield. (galchimia.com)
- While to date it has been necessary to use corrosive chemicals, high temperatures, and expensive metal catalysts to produce sulfonamides, the new method requires only cheaper starting materials, electrical current, and largely safe solvents. (eurekalert.org)
Side effects2
- Sulfonamides may include side effects. (urdujobz.com)
- Older people may be more sensitive to the side effects of sulfonamides. (urdujobz.com)
Drug2
- Dapsone is a sulfonamide related drug that is used for the therapy of leprosy and dermatitits herpetiformis. (nih.gov)
- Finally, the clinical practices, policy debates, and legal infrastructure that arose in in the context of the sulfonamides provided a template for pediatric drug development going forward that exists into the current day. (nih.gov)
Study1
- Purpose: Phase II multicenter study investigated the efficacy and toxicity of the novel halogenated derivative of sulfaquixonaline Chloroquinoxaline Sulfonamide (CQS) in metastatic colorectal cancer. (elsevier.com)
Medical3
- Using pediatric patient records housed at the National Library of Medicine, Dr. Cynthia Connolly explore the transformation wrought by the sulfonamides in medical and nursing practice at Baltimore's Sydenham Hospital. (nih.gov)
- Tell your doctor about all your medical conditions - especially kidney, liver, or blood disorders - before taking sulfonamides. (urdujobz.com)
- Tell your healthcare provider that you are taking sulfonamides before performing any type of medical procedure, including a dental examination or procedure. (urdujobz.com)
Make1
- Sulfonamides can make you dizzy. (urdujobz.com)
Problems1
- Sulfonamides can cause blood problems, especially if taken for a long time. (urdujobz.com)
Standards1
- The color of unknown samples is compared to the color of the standards and the sulfonamides concentration of the samples is derived. (mzfoodtest.com)
Research1
- A research team at Johannes Gutenberg University Mainz (JGU) in Germany has developed a completely new, environmentally-friendly electrochemical procedure for producing sulfonamides rapidly and inexpensively. (eurekalert.org)